Company profile: AVEO Oncology
1.1 - Company Overview
Company description
- Provider of targeted cancer therapeutics and oncology development platforms. Products include FOTIVDA (tivozanib), an oral VEGFR TKI approved for relapsed/refractory advanced RCC. Pipeline includes ficlatuzumab (anti-HGF) for HNSCC, AV-380 (anti-GDF15) for cancer cachexia, and AV-203, a HER3 inhibitory antibody. Offers an integrated cancer biology and Human Response platform for efficient discovery and development.
Products and services
- FOTIVDA (tivozanib): An approved, oral once-daily VEGFR tyrosine kinase inhibitor that treats adult relapsed or refractory advanced renal cell carcinoma after two or more prior systemic therapies
- Human Response Platform: A proprietary, genetically-defined mouse model system that architects targeted oncology therapeutics by modeling human cancer to develop targeted oncology therapeutics
- AV-203: A clinical-stage ErbB3 (HER3) inhibitory antibody candidate engineered to block both ligand-dependent and ligand-independent ErbB3 signaling pathways across various cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AVEO Oncology
ECM Therapeutics
HQ: United States
Website
- Description: Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ECM Therapeutics company profile →
Century Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Century Therapeutics company profile →
Ceptaris
HQ: United States
Website
- Description: Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ceptaris company profile →
Scandinavian ChemoTech
HQ: Sweden
Website
- Description: Provider of cancer care technologies, including IQwave – TSE (Tumour Specific Electroporation), a device and method that enhances uptake of cytotoxic drugs into tumor cells via electroporation, and D-EECT (Dynamic‑ElectroEnhanced ChemoTherapy), a treatment protocol aimed at better clinical outcomes for palliative patients with large tumor burdens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scandinavian ChemoTech company profile →
Bellwether Bio
HQ: United States
Website
- Description: Provider of novel cell-free DNA-based diagnostic technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bellwether Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AVEO Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AVEO Oncology
2.2 - Growth funds investing in similar companies to AVEO Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AVEO Oncology
4.2 - Public trading comparable groups for AVEO Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →